Clinical Trials & Research
Search for Clinical Trials
Clinical Research Locations
NEW: USOR 18042 A Phase 2, Non-Randomized, Open Label, Single Arm, Multi-Center Study Of Talazoparib For Neoadjuvant Treatment Of Germline BRCA 1/2 Mutation Patients With Early Triple-Negative Breast Cancer. (C3441020)
USOR 17162 A Phase II, Randomized, Blinded, Placebo-Controlled Study, of MTIG7192A, an Anti-Tigit Antibody, in Combination with Atezolizumab in Chemotherapy Naive Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC.) USOR 17162/GO40290
USOR 16187: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301) USOR 16187
USOR 17186: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy versus Standard of Care Therapy For First Line Treatment of Metastatic Colorectal Cancer. (CA209-9X8) (USOR 17186)
USOR 17063/TSR-022: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors: NSCLC. USOR 17063 (4020-01-001)
USOR 17050 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL.) USOR 17050/GO39942. Contact Project Manager Status.
USOR 17093/CITADEL-205 A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Ka Inhibitor, In Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) - INCB050465-205.
USOR 16023 An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments. (IMMU-132-05)
USOR 17081 An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen. USOR 17081 (C16038) Ph4 Ixazomib+Lena & Dex MM (MM-6)
USOR 16164 Randomized, Multi-Center, Open-Label, Phase 3, Study of Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine vs. Oxaliplatin Plus Fluoropyrimidine in Subjects with Previously Untreated, Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. (BMS CA 209-649)
USOR 16195 A Phase 2, Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated, Unresectable, Locally Advanced or Metastatic HER2+ Breast Carcinoma. USOR 16195 (STAR ONT 380 206)
USOR 17082 A Randomized, Open-Label, Phase 3 Study for Patients With Node-Positive, Early Stage, HR+, HER2-, Breast Cancer. MonarchE is a Phase 3 Study of Abemaciclib Combined with Standard Adjuvant EndocrineTherapy vs Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer. USOR 17082 (I3Y-MC-JPCF) (Monarche)
USOR 16130 A Phase III Study of BBI-608 in Combination with 5-Fluorouracil, Leucovorin, Irinotecan (Folfiri) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC). (CanStem303C)
Available at: Arlington Heights
USOR 17041 Screening Protocol for STAR USOR 16248: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects with Diffuse Large B Cell Lymphoma. USOR 17041
USOR 16041 AN OPEN-LABEL PHASE 2 MULTI-COHORT TRIAL OF NIVOLUMAB IN ADVANCED OR METASTATIC MALIGNANCIES. HOLDING. CONTACT RESEARCH FOR OPEN COHORTS. USOR 16041 (CA 209-627)
AGIOS AG120-C-009 A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age and Older, with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation.
ECOG-ACRIN S1400 2nd Line A Phase II/III, Biomarker-Driven Master Protocol For Previously Treated Squamous Cell Lung Cancer. - A Phase II Study of Talazoparib in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer. - A Phase III Randomized Study of Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients with Stage IV Squamous Lung Cancer and No Matching Biomarker.
ECOG-ACRIN-4512 A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib vs Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.
ECOG-ACRIN 1910 A Phase III, Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL Negative B Lineage Acute Lymphoblastic Leukemia in Adults.
ECOG-ACRIN S1207 A Phase III, Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer.
ECOG-ACRIN 1131 A Randomized, Phase III Post-Operative Trial of Platinum Base Chemotherapy vs Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Therapy.
USOR 16140 GRAIL 001 THE CIRCULATING CELL-FREE GENOME ATLAS STUDY (CCGA.) A Prospective, Multi-Center, Observational Study with Collections of De-Identified Biospecimens and Clinical Data from at Least 10,000 Participants from Clinical Networks in the United States, Canada and the United Kingdom. Next Generation Sequencing (NGS) based assay(s) of Nucleic Acids (NAs) Isolated From Peripheral Blood and Tumor Tissues.
USOR 16035 Registry - A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - The Insight MM Study. (NSMM-5001)
USOR 16065 Relapsed/Refractory - A Phase 2b, Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma. (UTX-TGR-205)
USOR 11282 1st Line - A Phase 2, Single-Arm, Open-Label Study of Single-Agent Brentuximab Vedotin for Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above.(SGN35-015)
USOR 16100 Hodgkins Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices. (CA20965)
USOR 16156 A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer. (CA209-817)
USOR 16161 A Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab Versus Platinum-Doublet Chemotherapy in Early Stage NSCLC. (CA209-816)
USOR 16128 POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study. (A5481081)
USOR 16160 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONROLLED, MULTICENTER TRIAL, TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WITH PTEN-LOSS (PTEN DIAGNOSTIC POSITIVE) TUMORS. (ROCHE CO 39303)
Available at: Arlington Heights